• In early August 2026, Exelixis reported past second-quarter results showing revenue of US$628.69 million and net income of US$212.05 million, while slightly trimming its full-year 2026 revenue outlook to US$2.50 billion–US$2.55 billion and filing a US$112 million employee stock plan-related shelf registration.
• Alongside these financial updates, Exelixis highlighted continued progress of its oncology pipeline, including zanzalintinib as a potential second franchise, reinforcing its effort to diversify beyond cabozantinib.
• We’ll now examine how Exelixis’ raised profitability in Q2 2026 and modestly lower revenue guidance reshape the company’s broader investment narrative.

AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Exelixis Investment Narrative Recap

To own Exelixis, you need to believe that cash flows from cabozantinib can bridge the company to a more diversified oncology portfolio anchored by zanzalintinib. The latest Q2 2026 results, with higher profitability but slightly lower full year revenue guidance, do not materially change that core bet. Near term, the key catalyst remains the December 2026 PDUFA decision for zanzalintinib in colorectal cancer, while dependence on cabozantinib remains the central risk.

Among the recent updates, the modest trim to 2026 revenue guidance to US$2.50 billion to US$2.55 billion is most relevant here. It subtly tightens the gap between consensus expectations and the more bullish scenarios that assume faster growth from cabozantinib and future contributions from zanzalintinib. How investors interpret this guidance shift in light of upcoming trial readouts and the PDUFA decision will likely shape how much confidence they place in Exelixis’ transition beyond a single flagship drug.

Yet beneath the solid Q2 numbers, one key concern investors should be aware of is cabozantinib’s heavy revenue concentration and potential exposure to...

Exelixis' narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029.

Uncover how Exelixis' forecasts yield a $49.65 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Exelixis could reach about US$3.8 billion in revenue and US$1.5 billion in earnings by 2029, which is far more bullish than consensus and makes the recent guidance cut and ongoing cabozantinib dependence a useful test of how realistic those forecasts really are.

Explore 6 other fair value estimates on Exelixis - why the stock might be worth just $49.07!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.